Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-6.69 Insider Own17.80% Shs Outstand5.37M Perf Week-2.90%
Market Cap20.67M Forward P/E- EPS next Y-3.41 Insider Trans0.00% Shs Float4.42M Perf Month8.15%
Income-26.23M PEG- EPS next Q-0.97 Inst Own50.57% Short Float1.28% Perf Quarter-20.29%
Sales52.90M P/S0.39 EPS this Y89.41% Inst Trans-28.00% Short Ratio5.74 Perf Half Y-54.71%
Book/sh1.27 P/B3.04 EPS next Y-30.15% ROA-32.24% Short Interest0.06M Perf Year-45.84%
Cash/sh2.94 P/C1.31 EPS next 5Y3.20% ROE-478.86% 52W Range3.26 - 9.56 Perf YTD3.22%
Dividend Est.- P/FCF- EPS past 5Y4.85% ROI-152.50% 52W High-59.74% Beta1.19
Dividend TTM- Quick Ratio1.06 Sales past 5Y27.16% Gross Margin85.63% 52W Low18.10% ATR (14)0.25
Dividend Ex-Date- Current Ratio1.06 EPS Y/Y TTM68.95% Oper. Margin-49.44% RSI (14)51.75 Volatility6.79% 5.92%
Employees222 Debt/Eq1.88 Sales Y/Y TTM50.69% Profit Margin-49.57% Recom1.00 Target Price18.00
Option/ShortNo / Yes LT Debt/Eq1.53 EPS Q/Q87.57% Payout- Rel Volume2.20 Prev Close3.68
Sales Surprise175.70% EPS Surprise57.95% Sales Q/Q60.28% EarningsNov 13 AMC Avg Volume9.87K Price3.85
SMA202.72% SMA504.10% SMA200-36.76% Trades Volume21,754 Change4.62%
Date Action Analyst Rating Change Price Target Change
Apr-21-21Initiated BofA Securities Buy $12
Feb-01-21Initiated UBS Neutral $13
Sep-08-20Initiated Jefferies Buy $21
Mar-25-20Initiated Stifel Buy $19
Feb-27-20Initiated Barclays Overweight $22
Apr-29-19Initiated UBS Buy $12
Dec-11-18Initiated Oppenheimer Outperform $15
Oct-08-18Initiated Laidlaw Buy $18
Mar-04-24 08:11AM
Feb-08-24 05:55PM
Nov-13-23 04:11PM
Nov-02-23 04:11PM
Nov-01-23 04:12PM
04:11PM Loading…
Sep-28-23 04:11PM
Aug-25-23 08:50AM
Aug-11-23 11:22AM
Aug-10-23 08:08AM
Aug-04-23 09:16AM
Aug-02-23 04:11PM
Jul-20-23 06:55AM
Jul-13-23 08:14AM
Jun-16-23 08:56PM
Jun-01-23 07:57AM
05:10PM Loading…
May-26-23 05:10PM
May-15-23 04:13PM
May-04-23 10:00AM
Apr-17-23 08:00AM
Apr-07-23 06:50PM
Mar-30-23 07:25PM
Mar-09-23 10:02AM
Mar-01-23 04:44PM
Dec-02-22 05:02PM
Nov-23-22 04:30PM
Nov-13-22 07:39AM
Nov-10-22 05:55PM
Nov-04-22 11:00AM
04:52PM Loading…
Aug-31-22 04:52PM
Aug-17-22 06:17AM
Aug-11-22 04:10PM
Aug-08-22 10:00AM
Aug-04-22 10:00AM
Jun-06-22 08:00AM
May-17-22 04:05PM
May-12-22 04:30PM
May-10-22 05:25PM
May-06-22 10:18AM
May-05-22 05:55PM
May-04-22 07:25AM
Apr-12-22 07:30AM
Apr-08-22 08:00AM
Mar-28-22 04:30PM
Mar-18-22 12:39PM
Mar-02-22 08:00AM
Mar-01-22 08:00AM
Jan-17-22 07:08AM
Nov-30-21 05:30PM
Nov-18-21 08:00AM
Nov-16-21 09:06AM
Nov-15-21 12:25PM
Oct-28-21 03:05PM
Oct-12-21 09:08AM
Sep-22-21 03:24AM
Sep-20-21 08:00AM
Sep-14-21 12:09PM
Aug-12-21 08:05PM
Aug-05-21 10:50AM
Jul-29-21 03:05PM
Jul-21-21 03:20PM
Jul-19-21 05:27AM
Jul-09-21 08:00AM
Jul-06-21 08:00AM
Jun-30-21 08:30AM
May-18-21 03:04AM
May-13-21 07:50PM
Apr-20-21 11:36AM
Apr-12-21 07:00AM
Apr-05-21 04:12PM
Mar-21-21 03:37AM
Mar-18-21 04:30PM
Feb-26-21 08:00AM
Feb-21-21 03:02AM
Feb-18-21 07:30AM
Feb-17-21 04:05PM
Feb-11-21 09:13AM
Feb-08-21 06:20AM
Jan-19-21 08:00AM
Dec-21-20 04:30PM
Dec-18-20 10:21PM
Nov-30-20 09:54PM
Nov-28-20 11:30PM
Nov-25-20 10:10PM
Nov-23-20 11:15PM
Nov-21-20 11:23PM
Nov-18-20 10:00PM
Nov-16-20 09:30PM
Nov-14-20 06:00PM
Nov-12-20 12:04PM
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariepy, and Leigh Revers in 2000 and is headquartered in Austin, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH TARGET N V10% OwnerJul 17Buy0.474,255,3192,000,00015,447,322Jul 19 03:14 PM